Source-grounded facts extracted from Prelude Therapeutics Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Prelude Therapeutics Inc shareholders approved Advisory vote on the frequency of advisory votes on the compensation for the Company's named executive officers at the 2026-06-09 meeting.
“4. Advisory vote on the frequency of advisory votes on the compensation for the Company's named executive officers, based on the following votes: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 26,877,941 65,638 103,237 5,941 4,799,016”
Prelude Therapeutics Inc shareholders approved Advisory vote to approve the 2025 compensation for the Company's named executive officers at the 2026-06-09 meeting.
“3. Advisory vote to approve the 2025 compensation for the Company's named executive officers, based on the following votes: Shares For Shares Against Shares Abstaining Broker Non-Votes 26,869,142 107,500 76,115 4,799,016”
Prelude Therapeutics Inc shareholders approved Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
“2. Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026, based on the following votes: Shares For Shares Against Shares Abstaining Broker Non-Votes 31,841,080 4,951 5,742 0”
Prelude Therapeutics Inc shareholders approved Election of three Class III Directors, Krishna Vaddi, Paul Scherer, and Katina Dorton, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director’s earlie at the 2026-06-09 meeting.
“On June 9, 2026, Prelude Therapeutics Incorporated (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") and the following proposals were approved by the Company's stockholders: 1. Election of three Class III Directors, Krishna Vaddi, Paul Scherer, and Katina Dorton, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director’s earlier resignation or removal, based on the following votes: Nominees Shares For Shares Withheld Broker Non-Votes Krishna Vaddi, Ph.D. 26,996,820 55,937 4,799,016 Paul Scherer, MD, Ph.D. 25,532,267 1,520,490 4,799,016 Katina Dorton, J.D., MBA 26,998,601 54,156 4,799,016”
Prelude Therapeutics Inc reported financial results for the three months ended March 31, 2026.
“On May 12, 2026, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2026.”
Prelude Therapeutics Inc entered into Underwriting Agreement with Goldman Sachs & Co. LLC and Evercore Group L.L.C. (effective 2026-04-20).
“On April 20, 2026, Prelude Therapeutics Incorporated (“Prelude”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Evercore Group L.L.C. as representatives (the “Representatives”) of the underwriters named therein”
Prelude Therapeutics Inc reported financial results for the full year ended December 31, 2025.
“Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the full year ended December 31, 2025”
Prelude Therapeutics Inc issued 6,250,000 shares of common stock to Incyte Corporation for $4.00 per share for a total of $25 million.
“the Company entered into a securities purchase agreement with Incyte (the "Securities Purchase Agreement"), pursuant to which Incyte has agreed to purchase 6,250,000 shares (the "Shares") of the Company’s non-voting common stock (the "Non-Voting Common Stock") at a price of $4.00 per share for a total of $25 million.”
Paul Scherer was appointed as Class III Director at Prelude Therapeutics Inc.
“the Board appointed Paul Scherer, M.D., as a Class III director and as a member of the Compensation committee and the Governance Committee of the Board, effective as of the adjournment of the 2025 Annual Meeting of Stockholders (the “ Annual Meeting ”) on June 12, 2025”
Prelude Therapeutics Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“March 27, 2025, Prelude Therapeutics Inc (the “Company”) received a letter (the “Bid Price Notice”) from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Bi”
Bryant D. Lim was appointed as Chief Financial Officer at Prelude Therapeutics Inc.
“On February 3, 2025 (the “Effective Date”), the Board approved the appointment of Mr. Lim as the Company’s permanent Chief Financial Officer, effective as of the Effective Date.”
Prelude Therapeutics Inc reported financial results for first quarter ended March 31, 2024.
“On May 7, 2024, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024.”
Bryant D. Lim was appointed as interim Chief Financial Officer at Prelude Therapeutics Inc.
“Effective as of the Effective Date, the Board of Directors of the Company appointed Bryant D. Lim, the Company’s Chief Legal Officer and Corporate Secretary, as its interim Chief Financial Officer.”
Laurent Chardonnet departed as Chief Financial Officer at Prelude Therapeutics Inc.
“On April 8, 2024 (the “Effective Date”), Prelude Therapeutics Incorporated (the “Company”) and Laurent Chardonnet, the Company’s Chief Financial Officer, agreed that he will no longer serve as the Company’s Chief Financial Officer, effective as of the Effective Date.”
Prelude Therapeutics Inc reported financial results for the fiscal year ended December 31, 2023.
“Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the year ended December 31, 2023.”
Prelude Therapeutics Inc entered into Amended and Restated Registration Rights Agreement with the Company and the Purchasers (effective 2023-12-11).
“the Company and the Purchasers also entered into an Amended and Restated Registration Rights Agreement, dated as of December 11, 2023 (the “ Amended and Restated Registration Rights Agreement ”), providing for the registration for resale of the shares of Common Stock underlying the Pre-Funded Warrants”
Prelude Therapeutics Inc entered into Securities Purchase Agreement with certain institutional accredited investors (effective 2023-12-11).
“On December 11, 2023, Prelude Therapeutics Incorporated, a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to 7,936,759 shares of the Company’s voting common stock, par value $0.0001 per share (the “ Common Stock ”), at a price of $3.1499 per warrant with an exercise price of $0.0001 per share”
Prelude Therapeutics Inc reported financial results for the three months ended September 30, 2023.
“On November 1, 2023, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2023.”
Prelude Therapeutics Inc shareholders approved Approval of an amendment to the Company's Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation at the 2023-06-16 meeting.
“Approval of an amendment to the Company's Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.”
Prelude Therapeutics Inc shareholders approved Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023 at the 2023-06-16 meeting.
“Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.”
Prelude Therapeutics Inc shareholders approved Election of two Class III Directors, Krishna Vaddi, Ph.D., and Mardi C. Dier at the 2023-06-16 meeting.
“Election of two Class III Directors, Krishna Vaddi, Ph.D., and Mardi C. Dier, each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director's earlier resignation or removal.”
Prelude Therapeutics Inc entered into Underwriting Agreement with Morgan Stanley & Co. LLC (effective 2023-05-18).
“On May 18, 2023, Prelude Therapeutics Incorporated (“ Prelude ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC as representative (the “ Representative ”) of the underwriters named therein (the “ Underwriters ”), pursuant to which Prelude agreed to issue and sell an aggregate of (a) 4,496,744 shares of its common stock, which comprise (i) 3,048,522 shares of its voting common stock, par value $0.0001 per share (the “ Voting Common Stock ”) and (ii) 1,448,222 shares of its non-voting common stock, par value $0.0001 per share (the “ Non-Voting Common Stock ,” and together with the Voting Common Stock, the “ Shares ”), at a price to the public of $5.75 per share, and (b) pre-funded warrants to purchase up to 12,895,256 shares of the Company’s Voting Common Stock (the “ Pre-Funded Warrants ”), at a price to the public of $5.7499 per warrant with an exercise price of $0.0001 per share (the “ Offering ”).”
Prelude Therapeutics Inc reported first quarter ended March 31, 2023 results: net income $27.7 million, EPS $0.58 per share.
“Net Loss: For the three months ended March 31, 2023, net loss was $27.7 million, or $0.58 per share compared to $29.5 million, or $0.63 per share, for the prior year period.”
Prelude Therapeutics Inc entered into Sales Agreement with Jefferies LLC valued at up to $75.0 million (effective 2023-03-15).
“On March 15, 2023, Prelude Therapeutics Incorporated (the “Company”), entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC, as sales agent and/or principal (“Jefferies”), pursuant to which the Company may offer and sell, from time to time to or through Jefferies, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $75.0 million (the “Shares”).”
Prelude Therapeutics Inc reported financial results for fiscal year ended December 31, 2022.
“On March 15, 2023, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the year ended December 31, 2022.”
Prelude Therapeutics Inc: Adopted amended and restated bylaws to implement changes related to universal proxy rules, recent DGCL amendments, and other procedural and administrative updates, effective January 19, 2023 (effective 2023-01-19).
“On January 19, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Prelude Therapeutics Incorporated (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.”
Prelude Therapeutics Inc reported financial results for the third quarter ended September 30, 2022.
“On November 14, 2022, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2022.”
Deborah Morosini resigned as EVP and Chief of Clinical Affairs at Prelude Therapeutics Inc.
“On April 6, 2022 (the “ Effective Date ”), Prelude Therapeutics Incorporated (the “ Company ”) and Deborah Morosini, the Company’s EVP and Chief of Clinical Affairs, agreed that, effective as of the Effective Date, Dr. Morosini shall resign from her role as an officer of the Company”
Jane Huang was appointed as President and Chief Medical Officer at Prelude Therapeutics Inc.
“the Board of Directors of the Company (the “ Board ”) appointed Jane Huang, M.D., age 49, as the President and Chief Medical Officer of the Company, effective on or about April 4, 2022”
Laurent Chardonnet was appointed as Chief Financial Officer at Prelude Therapeutics Inc.
“On November 5, 2021, the Board of Directors of the Company (the “Board”) appointed Laurent Chardonnet as the Chief Financial Officer of the Company, including as the “principal financial officer” and “principal accounting officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective on or about November 29, 2021.”
Brian Piper resigned as Chief Financial Officer at Prelude Therapeutics Inc.
“On November 5, 2021, Brian Piper, the Chief Financial Officer of the Company, notified the Company that he will be resigning from the Company, effective November 19, 2021, to pursue other opportunities.”
Christopher Pierce resigned as Executive Vice President and Chief of Business Operations at Prelude Therapeutics Inc.
“On September 16, 2021, Prelude Therapeutics Incorporated. (the “Company”) received notice from Christopher Pierce of his intention to resign as Executive Vice President and Chief of Business Operations of the Company effective on September 30, 2021, in order to pursue another employment opportunity.”
Martin Babler was appointed as Class II director at Prelude Therapeutics Inc.
“the Board appointed Martin Babler as a Class II director and as a member of the Audit Committee of the Board, effective as of July 19, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.